Emerging Therapies for Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) arises from hepatocytes and accounts for 90% of primary liver cancer. According to Global Cancer Incidence, Mortality and Prevalence (GLOBOCAN) 2020, globally HCC is the sixth most common cancer and the third most common cause of cancer-related deaths. Reasons for HCC prognosis remaining dismal are that HCC is asymptomatic in its early stages, leading to late diagnosis, and it is markedly resistant to conventional chemo- and radiotherapy. Liver transplantation is the treatment of choice in early stages, while surgical resection, radiofrequency ablation (RFA) and trans arterial chemoembolization (TACE) are Food and Drug Administration (FDA)-approved treatments for advanced HCC.…

• NC
  National Cancer Institute

  Awards: 2R01DK107451-05, 1R01CA240004-01, 1R01CA230561-01A1, 1R01CA244993-01
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Awards: 1R01CA230561-01A1, 1R01CA240004-01, 1R01CA244993-01, 2R01DK107451-05